Cargando…
Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
BACKGROUND: Ameloblastomas are uncommon locally aggressive tumors of odontogenic epithelium that rarely metastasize. Currently, there is no standard of care for the metastatic forms. Several studies have shown that ameloblastomas frequently have a BRAF mutation. CASE PRESENTATION: We report a case o...
Autores principales: | Broudic-Guibert, Morgane, Blay, Jean-Yves, Vazquez, Léa, Evrard, Alexandre, Karanian, Marie, Taïeb, Sophie, Hoog-Labouret, Natalie, Oukhatar, Céline Mahier Ait, Boustany-Grenier, Rania, Arnaud, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657072/ https://www.ncbi.nlm.nih.gov/pubmed/31340860 http://dx.doi.org/10.1186/s13256-019-2140-6 |
Ejemplares similares
-
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016) -
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023) -
In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
por: Żołek, Teresa, et al.
Publicado: (2023) -
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017) -
BRAF inhibitor: a novel therapy for ameloblastoma in mandible
por: Abe, Masanobu, et al.
Publicado: (2018)